Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Professional Survey Report 2019

Table of Contents

Executive Summary

1 Industry Overview of Chemotherapy Induced Peripheral Neuropathy Treatment

• 1.1 Definition of Chemotherapy Induced Peripheral Neuropathy Treatment
• 1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
  • 1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 APX-3330
  • 1.2.3 BR-297
  • 1.2.4 Cannabidiol
  • 1.2.5 Dimiracetam
  • 1.2.6 Others
• 1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Applications
  • 1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Clinic
  • 1.3.3 Hospital
  • 1.3.4 Others
• 1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Overall Market
  • 1.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2014-2025)
  • 1.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production (2014-2025)
  • 1.4.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2014-2025)
  • 1.4.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2014-2025)
  • 1.4.5 China Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2014-2025)
  • 1.4.6 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2014-2025)
  • 1.4.8 India Chemotherapy Induced Peripheral Neuropathy Treatment Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
• 2.3 Manufacturing Process Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment
• 2.4 Industry Chain Structure of Chemotherapy Induced Peripheral Neuropathy Treatment

3 Development and Manufacturing Plants Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Chemotherapy Induced Peripheral Neuropathy Treatment
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Production and Capacity Analysis
• 4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Analysis
• 4.3 Chemotherapy Induced Peripheral Neuropathy Treatment Price Analysis
• 4.4 Market Concentration Degree

5 Chemotherapy Induced Peripheral Neuropathy Treatment Regional Market Analysis

• 5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Production by Regions
  • 5.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production by Regions
  • 5.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Regions
• 5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Regions
• 5.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
  • 5.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Production
  • 5.3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Import and Export
• 5.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
  • 5.4.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Production
  • 5.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Import and Export
• 5.5 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
  • 5.5.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Production
  • 5.5.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Chemotherapy Induced Peripheral Neuropathy Treatment Import and Export
• 5.6 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
  • 5.6.1 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Production
  • 5.6.2 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Import and Export
• 5.7 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
  • 5.7.1 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Production
  • 5.7.2 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Import and Export
• 5.8 India Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis
  • 5.8.1 India Chemotherapy Induced Peripheral Neuropathy Treatment Production
  • 5.8.2 India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Chemotherapy Induced Peripheral Neuropathy Treatment Import and Export

6 Chemotherapy Induced Peripheral Neuropathy Treatment Segment Market Analysis (by Type)

• 6.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Production by Type
• 6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type
• 6.3 Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type

7 Chemotherapy Induced Peripheral Neuropathy Treatment Segment Market Analysis (by Application)

• 7.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
• 7.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Share by Application (2014-2019)

8 Chemotherapy Induced Peripheral Neuropathy Treatment Major Manufacturers Analysis

• 8.1 Achelios Therapeutics Inc
  • 8.1.1 Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.1.2 Achelios Therapeutics Inc Product Introduction, Application and Specification
  • 8.1.3 Achelios Therapeutics Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 Advinus Therapeutics Ltd
  • 8.2.1 Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.2.2 Advinus Therapeutics Ltd Product Introduction, Application and Specification
  • 8.2.3 Advinus Therapeutics Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 Apollo Endosurgery Inc
  • 8.3.1 Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.3.2 Apollo Endosurgery Inc Product Introduction, Application and Specification
  • 8.3.3 Apollo Endosurgery Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Aptinyx Inc
  • 8.4.1 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.4.2 Aptinyx Inc Product Introduction, Application and Specification
  • 8.4.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 Asahi Kasei Pharma Corp
  • 8.5.1 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.5.2 Asahi Kasei Pharma Corp Product Introduction, Application and Specification
  • 8.5.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Can-Fite BioPharma Ltd
  • 8.6.1 Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.6.2 Can-Fite BioPharma Ltd Product Introduction, Application and Specification
  • 8.6.3 Can-Fite BioPharma Ltd Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 Celgene Corp
  • 8.7.1 Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.7.2 Celgene Corp Product Introduction, Application and Specification
  • 8.7.3 Celgene Corp Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 DermaXon LLC
  • 8.8.1 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.8.2 DermaXon LLC Product Introduction, Application and Specification
  • 8.8.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 Eisai
  • 8.9.1 Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.9.2 Eisai Product Introduction, Application and Specification
  • 8.9.3 Eisai Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Immune Pharmaceuticals Inc
  • 8.10.1 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production Sites and Area Served
  • 8.10.2 Immune Pharmaceuticals Inc Product Introduction, Application and Specification
  • 8.10.3 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 INSYS Therapeutics Inc
• 8.12 Kineta Inc
• 8.13 KPI Therapeutics Inc
• 8.14 Krenitsky Pharmaceuticals Inc
• 8.15 MAKScientific LLC
• 8.16 Metys Pharmaceuticals AG
• 8.17 Midatech Pharma US Inc
• 8.18 Mundipharma International Ltd
• 8.19 Nemus Bioscience Inc
• 8.20 Neurocentrx Pharma Ltd

9 Development Trend of Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 9.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Trend Analysis
  • 9.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Regional Market Trend
  • 9.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Forecast 2019-2025
  • 9.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Forecast 2019-2025
  • 9.2.3 China Chemotherapy Induced Peripheral Neuropathy Treatment Forecast 2019-2025
  • 9.2.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Forecast 2019-2025
  • 9.2.5 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Forecast 2019-2025
  • 9.2.6 India Chemotherapy Induced Peripheral Neuropathy Treatment Forecast 2019-2025
• 9.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Trend (Product Type)
• 9.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List